Castle Biosciences Inc. (CSTL) Reports Prelim Q4 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St hits two-week lows as rising bond yields, Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results
January 8, 2023 7:00 PM EST2022 total revenue expected to meet or exceed top end of guided range of $132137 million
Delivered 44,338 total test reports in 2022, an increase of 58% compared to 2021
Growth of 37% year over year in DecisionDx®-Melanoma test report volume
Year-end 2022 cash, cash equivalents and marketable investment securities expected to be approximately $259 million
FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results... More
